MedTrace Logo

Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease

NCT00304161 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-01-30

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.

Conditions

  • Depressive Disorder
  • Parkinson Disease

Interventions

DRUG

Atomoxetine

40 to 80 mg orally once daily for 8 weeks

DRUG

Placebo

40 to 80 mg orally once daily for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Daniel Weintraub, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304161 on ClinicalTrials.gov